Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+
- 31 August 2004
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 31 (6) , 821-824
- https://doi.org/10.1016/j.nucmedbio.2004.03.008
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivityEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapyApplied Radiation and Isotopes, 2002
- Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology groupSeminars in Nuclear Medicine, 2002
- Complexation studies with 90Y from a novel 90Sr-90Y generatorRadiochimica Acta, 2001
- Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotideEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- DOTATOC: a powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA 0 , d -Phe 1 ,Tyr 3 ]octreotide, a promising somatostatin analogue for radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997